A recent study (AKN Pedersen et al. JPEN https://doi.org/10.1002/jpen.1593) shows the utility of obtaining urine spot sodiums in patients with an ileostomy. Thanks to Kipp Ellsworth for sharing this reference.
Full link: A Single Urine Sodium Measurement May Validly Estimate 24‐hour Urine Sodium Excretion in Patients With an Ileostomy
Background: Sodium deficiency in patients with an ileostomy is associated with chronic dehydration and may be difficult to detect. We aimed to investigate if the sodium concentration in a single spot urine sample may be used as a proxy for 24‐hour urine sodium excretion.
Design: In this prospective, observational study, we included 16 adult individuals: 8 stable patients with an ileostomy and 8 healthy volunteers with intact intestines
- There was a high and statistically significant correlation between 24‐hour natriuresis and urine sodium concentrations in both morning spot samples (n = 8, Spearman’s rho [ρ] = 0.78, P = 0.03) and midday spot samples (n = 8, ρ = 0.82, P = 0.02) in the patients with an ileostomy.
My take: In patients with ileostomy (and also short bowel syndrome), periodic urine sodium values (from morning or mid-day) will help detect subclinical sodium depletion.
Related blog posts:
Atlanta Botanical Gardens
1. From the recent Advances in IBD Conference, Healio Gastroenterology reports on Dr. Baldassano’s update on PLEASE study which examined enteral nutrition in comparison to anti-TNF therapy. Here’s the link: Enteral Nutrition Outcomes (Thanks to Kipp Ellsworth for this reference)
Here’s an excerpt:
Citing the findings from the Pediatric Longitudinal Study of Semi-Elemental Diet and Stool Microbiome (PLEASE), Baldassano demonstrated that greater mucosal healing was achieved in CD patients on exclusive enteral nutrition compared with partial enteral nutrition therapy. In this prospective cohort study, 38 children received enteral therapy with defined formula diet and 52 controls received anti-TNF-alpha therapy. The enteral nutrition group was further stratified to evaluate mucosal healing on a more restrictive diet; one subgroup received 80% to 90% of total caloric needs from enteral therapy, of which 14% achieved induction of remission at 8 weeks, the other subgroup received 90% to 100% of total caloric needs from enteral therapy, of which 45% achieved remission, and 62% of controls achieved remission.
2. NEJM 2014; 371: 2418-27. This is a case report of a 9-year-old with Crohn’s Disease and pulmonary nodules. This report serves as a useful review.
3. Standardized use of fecal calprotectin (here’s the link -from KT Park’s Twitter feed):
Fecal calprotectin -use for identifying IBD and for identifying relapse risk
4. Inflamm Bowel Dis 2014; 20: 2247-59. Study examined factors associated with infliximab clearance. Higher clearance noted with low albumin, high body weight, and the presence of antibodies to infliximab (ATI). The authors note that higher concentrations with dose escalation are more likely when the dose interval was shortened than by increasing the administered dose.
5. Inflamm Bowel Dis 2014; 20: 2260-65. “Natural History of Perianal Crohn’s Disease After Fecal Diversion.” Despite greater use of biologics, only 15 of 49 patients reestablished intestinal continuity between 2000-2011. In this group of 15, only 5 remained reconnected and 3 of these 5 patients had procedures to control sepsis. The likelihood of sustained intestinal continuity remains low in patients who have required a diverting procedure.
Related blog posts:
Sandy Springs, Georgia